Congenital Sucrase-Isomaltase Deficiency clinical trials at UCSF
1 research study open to eligible people
Congenital Sucrase-Isomaltase Deficiency is an illness that makes it hard to digest certain sugars. UCSF has a clinical trial to see if a medicine called Sucraid can help with symptoms. People with low, moderate, or normal sucrase levels can participate in a 7-day study using Sucraid. The trial is only in the United States and has multiple centers.
7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels
open to eligible people ages 6 months to 17 years
This is a Phase 4, U.S. only, multi-center study using a 7-day therapeutic response dose (TRD) of commercial Sucraid® to assess the response of treatment in 1100 symptomatic pediatric (6 months to 17 years old) subjects with low, moderate, and normal sucrase activity determined by a disaccharidase assay via EGD within 1 year of the Screening Visit. This study will also explore the relationship between known genetic CSID mutations and sucrase activities via (EGD) disaccharidase assay (low, moderate, and normal).
Oakland, California and other locations